If you want solid healthcare stocks that will be worth buying and holding for the next 10 years, you need to set the bar pretty high. But thanks to its portfolio and late-stage pipeline therapies, its next few years should feature strong growth.
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $313.57, marking a +0.56% move from the previous day.
Here's why they picked Gilead Sciences (NASDAQ: GILD), Johnson & Johnson (NYSE: JNJ), and Vertex Pharmaceuticals (NASDAQ: VRTX). David Jagielski (Gilead Sciences): Investors can minimize their risk in the event of a recession by investing in businesses that provide essential products and services and that also pay a dividend to help offset declines in the event of dropping share prices. Gilead Sciences meets both of those criteria, as its HIV treatments are vital to patients.